Abstract
In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 481-484 |
| Number of pages | 4 |
| Journal | Journal of radiation research |
| Volume | 51 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2 2010 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
- Radiation
- Health, Toxicology and Mutagenesis
Cite this
Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma. / Nonoshita, Takeshi; Shioyama, Yoshiyuki; Nakamura, Katsumasa; Nakashima, Torahiko; Saiji, Ohga; Yoshitake, Tadamasa; Ohnishi, Kayoko; Terashima, Kotaro; Asai, Kaori; Honda, Hiroshi.
In: Journal of radiation research, Vol. 51, No. 4, 02.08.2010, p. 481-484.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma
AU - Nonoshita, Takeshi
AU - Shioyama, Yoshiyuki
AU - Nakamura, Katsumasa
AU - Nakashima, Torahiko
AU - Saiji, Ohga
AU - Yoshitake, Tadamasa
AU - Ohnishi, Kayoko
AU - Terashima, Kotaro
AU - Asai, Kaori
AU - Honda, Hiroshi
PY - 2010/8/2
Y1 - 2010/8/2
N2 - In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.
AB - In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=77954995293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954995293&partnerID=8YFLogxK
U2 - 10.1269/jrr.09134
DO - 10.1269/jrr.09134
M3 - Article
C2 - 20601829
AN - SCOPUS:77954995293
VL - 51
SP - 481
EP - 484
JO - Journal of Radiation Research
JF - Journal of Radiation Research
SN - 0449-3060
IS - 4
ER -